Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Capital Analysis On China’s Health Care Mergers And Acquisitions

This article was originally published in PharmAsia News

Executive Summary

Government, private and foreign funds look set to be the three main cornerstones that shape China's health care market. According to industry analysis from 2004 - 2006, domestic capital led with a higher-than-expected 86 percent of the total mergers and acquisitions amount, way ahead of the 14 percent from foreign companies, even though the latter showed continuous growth. Out of the local monies injected into mergers and acquisitions, the 47 percent from the private sector overtook state-owned funding of 39 percent. Private investors have clear acquisition targets and strategies, while state-linked enterprises' pursuits are often influenced by the government. Compared with domestic funding, foreign investment offers unmatched advantages such as substantial capital, advanced technologies, reliable product quality, effective management and wealth of experience. (Click here for more - Chinese language)

You may also be interested in...



Biologic Exclusivity Provisions In USMCA Are Boon To Generics Industry; BIO Is 'Tremendously Worried'

Revised North American trade deal touted as enabling Congress to address crisis of high drug prices; requirement for 10 years biologic exclusivity is removed and language to allow incentives for generics added.

Kite Readies A Second CAR-T For Filing As CD19 Competition Grows

The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year. 

US FDA Could Use More Foreign Investigators If It Could Find Them, Woodcock Says

Hiring travails, inspection pre-announcement, lack of translators highlighted in congressional hearing on FDA foreign inspections.

UsernamePublicRestriction

Register

SC068418

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel